Tonix Pharmaceuticals Holding Corp. said Nasdaq approved transferring its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market is expected to commence at the open of market on March 3, 2026, under the Company's existing ticker symbol "TNXP."

The uplisting to the Nasdaq Global Select Market reflects the Company's compliance with the Nasdaq Global Select Market's higher financial and corporate governance standards. The transition to this higher tier of the Nasdaq market may enhance the Company's visibility among institutional investors, improve liquidity and broaden market recognition.

"Uplisting to the Nasdaq Global Select Market is an important milestone for Tonix," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "We look forward to leveraging this enhanced platform to drive growth and create value for our shareholders. We're grateful for the support that has brought us here and excited about what's ahead."

The Nasdaq Global Select Market is the highest of the three Nasdaq market tiers and is designed for companies that meet higher financial, liquidity and corporate governance requirements than those of the Nasdaq Capital Market and the Nasdaq Global Market. The Company believes that trading on this tier will further enhance its reputation with customers, partners and investors. Companies at this level may experience increased trading volumes and greater access to institutional investors. Meeting the Global Select Market's higher financial and corporate governance standards may also signal to the market that a company has achieved financial and operational growth.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_478533411/2227/2026-05-04T21:00:16